Affimed Therapeutics Company
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Technology:
Atrificial Vectors and Immune Cells
Headquarters:
Heidelberg, Baden-Wurttemberg, Germany
Founded Date:
0200-01-01
Employees Number:
101-250
Funding Status:
Post-IPO Equity
Total Funding:
521900000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2022-04-17
Last Funding Type:
Post-IPO Debt
Register and Claim Ownership